TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07681713: Long-Term Efficacy Study of Vatiquinone for the Treatment of Friedreich's Ataxia (FA)

Sponsor: PTC Therapeutics · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 120 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$1,791,472

Rescue Site Savings

+$1,178,600

Unlock Full NCT07681713 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07681713 Rescue Dossier →